Skip to main content

ProQR Therapeutics N.V.

PRQR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001612940

In the last 90 days, ProQR Therapeutics N.V. insiders filed 4 open-market purchases and 0 sales; 70 institutions reported holding it in 13F filings for Q2 2026, worth $113.0M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding ProQR Therapeutics N.V. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of PRQR: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders4746−1
Shares21.2M16.7M−4.56M (−21.5%)
Value$15.9M$60.0M+$44.1M (+277.9%)

New holders (14)

Institutions that held ProQR Therapeutics N.V. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to PRQR in Q4 2022
InstitutionSharesValue% of portfolio
Ikarian Capital, LLC422,625$1.56M0.65%
Millennium Management LLC188,916$699.0K0.00%
AWM Investment Company, Inc.166,667$616.7K0.09%
Susquehanna International Group, LLP164,821$609.8K0.00%
Bank of Montreal102,551$381.5K0.00%
Boothbay Fund Management, LLC90,285$334.1K0.01%
Cubist Systematic Strategies, LLC85,247$315.4K0.00%
Gsa Capital Partners LLP21,514$80.0K0.01%
JustInvest LLC21,429$79.3K0.00%
Mariner, LLC18,334$68.0K0.00%
Belvedere Trading LLC11,357$42.0K0.02%
PFS Partners, LLC1,000$3.70K0.00%
Advisory Services Network, LLC200$7400.00%
GWM Advisors LLC200$10.00%

Sold out (15)

Institutions that held ProQR Therapeutics N.V. at the end of Q3 2022 and filed for Q4 2022 without it.